1. Medicines
  2. Haematology
  3. JAKAVI® (ruxolitinib)
  4. Real-world insights

Prescribing information

 

Real-world insights

Patients with MF aren’t receiving the relief they need when they need it1

Real-world insights show that 1 in 3 patients with MF who may be experiencing symptoms are on ‘watch and wait’.*1

In the REALISM UK study, watch and wait was the most commonly used overall management strategy for patients with MF (34%), followed by JAKAVI® (29%) and hydroxycarbamide (17%).*†1

1 in 2 patients with intermediate-2 or high-risk MF, or patients presenting with symptomatic disease failed to receive active treatment as an initial management strategy.*1

Bar graph showing Choice of first management strategy for IPSS intermediate-2 and high-risk MF patients

 

Identify patients who are eligible for active management
with JAKAVI®, and help preserve their QoL.2–9

 

JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.10

* Data from patients with MF analysed in the REALISM UK study (N=200).1
† Patients were managed by more than one strategy at any given time.1

IPSS,  International Prognostic Scoring System; JAK, janus kinase; MF, myelofibrosis;  QoL, quality of life.

  1. Mead A, et al. ASH 2019, 7–10 December; Florida, USA. Poster P-1671.
  2. Mesa R, et al. BMC Cancer. 2016;16:167.
  3. Vannucchi A, et al. Haematologica. 2015;100:1139–1145.
  4. Vannucchi A, et al. Ann Oncol. 2015;26:v85–99.
  5. Scottish Medicines Consortium. Ruxolitinib (as phosphate), 5 mg, 15 mg, & 20 mg tablets (JAKAVI®). SMC No 867/13, 2015. Available at: https://www.scottishmedicines.org.uk/media/2277/ruxolitinib_JAKAVI_final.... Last accessed April 2021.
  6. Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
  7. Harrison C, et al. N Engl J Med. 2012;366:787–798.
  8. Reilly J, et al. Br J Haematol. 2014;167:418–438.
  9. National Institute for Health and Care Excellence. Technology appraisal guidance [TA386]. Available at: https://www.nice.org.uk/guidance/ta386. Last accessed April 2021.
  10. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.

Download more real-world insights

Download

 
 

View resources available for you and your patients

Find out more

 
 
Rate this content: 
No votes yet
UK | May 2021 | 119379
Haematology
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]